New York – September 11, 2026 -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) faces a securities fraud class action after its shares plunged 64.5% following disclosures about alleged undisclosed changes to clinical trial statistics underlying its Duchenne muscular dystrophy therapy application.
Los Angeles – September 11, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 11, 2026.
The class action targets investors who purchased Capricor shares during this roughly seven-month window. Appointment as lead plaintiff is not a prerequisite for shareholders to participate in any eventual recovery.
San Francisco – September 11, 2026 -- Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have until September 11, 2026, to seek lead plaintiff status in a securities class action tied to the company's Duchenne muscular dystrophy therapy, deramiocel, as the FDA extends its review timeline.
On September 11, 2026, Capricor disclosed that the FDA extended the PDUFA target action date for its lead cell therapy deramiocel from September 11, 2026, to September 11, 2026. The agency classified the company's post-Advisory Committee submission as a major amendment, which included 24-month open-label extension data from the Phase 3 HOPE-3 study and a bid to narrow the therapy's indication to upper limb function.